Thrombophilia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Thrombophilia – Drugs In Development, 2024 report and make more profitable business decisions.
Thrombophilia is a condition where the blood clots too easily. It increases risk of deep vein thrombosis (DVT), a blood clot in a vein, usually the leg, and pulmonary embolism (PE), a clot in the lungs. The most common inherited form of thrombophilia is Factor V Leiden thrombophilia. It is caused by genetic problem with a protein responsible for clotting. Duplex ultrasonography is an imaging test that uses sound waves to look at the flow of blood in the veins and can help with diagnosis. Anticoagulants, compression stockings, andn intravenous unfractionated heparin can be used for the treatment.
The Thrombophilia drugs in development market research report provide comprehensive information on the therapeutics under development for Thrombophilia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombophilia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Thrombophilia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Thrombophilia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Thrombophilia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Thrombophilia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akari Therapeutics PlcAURA Biopharm AS
Austhera BioSciences Inc
Beth Israel Deaconess Medical Center
Cadrenal Therapeutics Inc
Johnson & Johnson
KeyMed Biosciences Inc
RemeGen Co Ltd
University College London
University Hospital of Angers
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Thrombophilia reports